Thomas Prebet, MD
Hematology · New Haven, CTNPI 1811369507
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,668 of the $41,968 with a category attached, or 85.0%. It is spread thinly across 9 manufacturers, the largest accounting for just 20.8%. Reporting peaked in 2019 at $24,191 and has fallen 79.4% since, to $4,988 in 2021.
Across 25 payments — averaging $1678.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$9K
- Jazz Pharmaceuticals Inc.$8K
- Novartis$7K
- Genentech USA, Inc.$6K
- Pfizer$3K
- AbbVie$3K
- plus $7K from 3 others
Across 80 payments — averaging $14,793 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$468K
- Boehringer Ingelheim$200K
- Institut DE Recherches Internationales Servier$165K
- Agios Pharmaceuticals, Inc.$164K
- Genentech, Inc.$108K
- AbbVie$45K
- plus $34K from 2 others
What the payments were for
- Consulting fees$35,66885%
- Speaking & faculty fees$3,4608%
- Travel & lodging$1,7484%
- Food & beverage$1,0933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 3 | $8,710 |
| Jazz Pharmaceuticals Inc. | 1 | $8,000 |
| Novartis | 5 | $7,354 |
| Genentech USA, Inc. | 8 | $5,706 |
| Pfizer | 2 | $2,991 |
| AbbVie | 1 | $2,700 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,640 |
| Agios Pharmaceuticals, Inc. | 2 | $2,340 |
| Daiichi Sankyo Inc. | 1 | $1,528 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,968 in reported general payments places this provider in the 85th percentile of 24 hematology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 23 | $496,659 |
| SprycelDasatinib | 28 | $451,543 |
| TasignaNilotinib Hcl | 18 | $240,789 |
| VenclextaVenetoclax | 20 | $66,357 |
| Hydroxyurea | 29 | $517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $2,640 | $496,65923 claims |
| NovartisTasigna | $7,354 | $240,78918 claims |
| AbbVieVenclexta | $2,700 | $66,35720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 24 hematology providers in Connecticut.
Other hematology in New Haven
- Thomas DuffyNew Haven$298K
- Layla van DorenNew Haven$142K
- Nikolai PodoltsevNew Haven$123K
- Natalia NeparidzeNew Haven$13K
- Anish ShardaNew Haven$10K
- Lohith GowdaNew Haven$5K
- Alan LebowitzNew Haven$144
- Richard TorresNew Haven$120
- Yifei ZhangNew Haven$71
- Stephanie HaleneNew Haven$31
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.